Please login to the form below
EpiPen
This page shows the latest EpiPen news and features for those working in and with pharma, biotech and healthcare.
Pfizer set to unveil Mylan merger and spin-off
Its biggest off-patent brands would include drugs such as Pfizer’s Lipitor, Viagra and Mylan’s Epipen. ... Current Mylan chief executive Heather Bresch – who shouldered blame for the controversy over the Epipen price rises in the US two years ago -
Latest news
-
Fireworks likely at Senate drug pricing hearing today
as Martin Shkreli’s former company Turing Pharma racking up the price of an old antibiotic and Mylan with its steep price increases for EpiPen, a life-saving treatment for severe
-
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more
Teva lifted by approval for EpiPen generic. The FDA has approved Teva’s version of Mylan’s EpiPen, making it the first generic competitor to the costly emergency allergy treatment. ... Mylan introduced its own authorised generic form of the EpiPen in
-
Making a list and checking it twice…
like that of Mylan and Epipen in 2016 and this theme is poised to continue for the foreseeable future.
-
Mylan facing US anticompetitive practice probe
Two leading members of the US Senate Judiciary Committee have called for an investigation into Mylan's adherence to market competition laws over its EpiPen sales practices. ... In a letter to the federal antitrust regulator, Grassley and Leahy said the
-
Pricing's dodos
And, as I prepared for an interview about my imminent new book, I took the news story about Mylan's EpiPen as an example.
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Change in the pharma industry is inevitable
And this survey was conducted before Mylan’s scandalous EpiPen price-hike. Change across the entire pharmaceutical industry is inevitable.
-
2016: The year when deal-makers took stock?
Fewer NCEs coming through. Politics and pricing certainly had an impact, with the US backlash against aggressive pharma pricing following Mylan's EpiPen debacle, itself coming on the heels of the
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
